{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-24-000081","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2024-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.155337+00:00","generated_at":"2026-05-30T13:48:26.339008+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Keros Therapeutics appoints Yung H. Chyung as Chief Medical Officer","bullets":["Dr. Chyung appointed Chief Medical Officer effective November 1, 2024, succeeding Simon Cooper.","He will receive an annual base salary of $510,000 and a target bonus of 40% of base salary.","Eligible for a stock option to purchase 110,000 shares vesting over four years.","Previously Executive VP and CMO at Tourmaline Bio (2022-2024) and CMO at Scholar Rock (2016-2022).","Company press release issued October 16, 2024, announcing the appointment."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-24-000081","json":"https://secwatch.observer/filing/0001664710-24-000081.json","markdown":"https://secwatch.observer/filing/0001664710-24-000081.md","text":"https://secwatch.observer/filing/0001664710-24-000081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000081/0001664710-24-000081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000081/kros-20241015.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T13:48:26.339008+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}